Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ -- Abbott today announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit ...

New York, USA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Overall, BTK ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

TAMPA, Fla., Jan. 16, 2025 /CNW/ -- Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the "MAGICAL ...

Please provide your email address to receive an email when new articles are posted on . In patients with CLTI, there was no difference in wound healing parameters between a drug-eluting scaffold and ...

-- ABSORB™ is Designed to Treat a Patient's Blocked Vessel and Then Dissolve, Leaving the Vessel Free of a Permanent Metallic Implant ABBOTT PARK, Ill., Sept. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT ...